BR112012015677A2 - Compostos farmacêuticos. - Google Patents

Compostos farmacêuticos.

Info

Publication number
BR112012015677A2
BR112012015677A2 BRBR112012015677-2A BR112012015677A BR112012015677A2 BR 112012015677 A2 BR112012015677 A2 BR 112012015677A2 BR 112012015677 A BR112012015677 A BR 112012015677A BR 112012015677 A2 BR112012015677 A2 BR 112012015677A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compounds
compounds
pharmaceutical
methods
well
Prior art date
Application number
BRBR112012015677-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Lixin Zhang
Graham Peter Trevitt
Hughes Miel
Frank Burkamp
Timothy Harrison
Andrew John Wilkinson
Charles-Henry Fabritius
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Publication of BR112012015677A2 publication Critical patent/BR112012015677A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
BRBR112012015677-2A 2009-12-23 2010-12-23 Compostos farmacêuticos. BR112012015677A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
BR112012015677A2 true BR112012015677A2 (pt) 2015-06-30

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
BRBR112012015677-2A BR112012015677A2 (pt) 2009-12-23 2010-12-23 Compostos farmacêuticos.

Country Status (21)

Country Link
US (1) US9221838B2 (https=)
EP (1) EP2516435B8 (https=)
JP (1) JP5923043B2 (https=)
KR (1) KR20140015157A (https=)
CN (1) CN102791708B (https=)
AU (1) AU2010334591C1 (https=)
BR (1) BR112012015677A2 (https=)
CA (1) CA2783340C (https=)
CY (1) CY1115686T1 (https=)
DK (1) DK2516435T3 (https=)
ES (1) ES2503794T3 (https=)
GB (1) GB0922589D0 (https=)
IL (1) IL220153A (https=)
MX (1) MX2012007274A (https=)
NZ (1) NZ600453A (https=)
PL (1) PL2516435T3 (https=)
PT (1) PT2516435E (https=)
RU (1) RU2579513C2 (https=)
SG (1) SG181517A1 (https=)
SI (1) SI2516435T1 (https=)
WO (1) WO2011077098A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
US11208478B2 (en) 2016-08-07 2021-12-28 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pT346 PDK1
PE20200696A1 (es) * 2017-06-22 2020-06-16 Curadev Pharma Ltd Moduladores de moleculas pequenas de sting humana
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
GB2600384A (en) * 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2025250545A1 (en) * 2024-05-28 2025-12-04 Alterome Therapeutics, Inc. Akt1 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT76853A (en) * 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8008317B2 (en) * 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
CA2726317A1 (en) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Also Published As

Publication number Publication date
CN102791708B (zh) 2016-03-02
HK1171013A1 (en) 2013-03-15
US9221838B2 (en) 2015-12-29
CY1115686T1 (el) 2017-01-25
WO2011077098A9 (en) 2012-04-19
IL220153A0 (en) 2012-07-31
PT2516435E (pt) 2014-11-13
CA2783340C (en) 2015-11-24
RU2012131115A (ru) 2014-01-27
MX2012007274A (es) 2012-10-03
EP2516435B1 (en) 2014-08-06
CN102791708A (zh) 2012-11-21
JP2013515710A (ja) 2013-05-09
AU2010334591B2 (en) 2014-04-10
SG181517A1 (en) 2012-07-30
AU2010334591A1 (en) 2012-06-21
JP5923043B2 (ja) 2016-05-24
GB0922589D0 (en) 2010-02-10
CA2783340A1 (en) 2011-06-30
US20130116243A1 (en) 2013-05-09
IL220153A (en) 2015-05-31
WO2011077098A1 (en) 2011-06-30
PL2516435T3 (pl) 2015-01-30
NZ600453A (en) 2013-10-25
EP2516435B8 (en) 2014-10-15
AU2010334591C1 (en) 2014-07-31
ES2503794T3 (es) 2014-10-07
KR20140015157A (ko) 2014-02-06
SI2516435T1 (sl) 2014-12-31
RU2579513C2 (ru) 2016-04-10
DK2516435T3 (da) 2014-10-13
EP2516435A1 (en) 2012-10-31

Similar Documents

Publication Publication Date Title
BR112012015677A2 (pt) Compostos farmacêuticos.
PY1212975A (es) Compuestos de azabiclo o quinuclidin-carbamato como inhibidores de glucosilceramida sintasa
WO2011033265A8 (en) Pharmaceutical compounds
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
CO6480975A2 (es) Mimetico de smac
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
CU24097B1 (es) Compuestos piridiloxi-indoles sustituidos como inhibidores del vegf-r2 útiles para el tratamiento de enfermedades proliferativas
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
TR201816379T4 (tr) DNA-PK inhibitörleri.
DOP2015000039A (es) Inhibidores de glucosilceramida sintasa
CR20140361A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
PH12013501618A1 (en) New azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
PH12013502059A1 (en) Pyrrolotriazinone derivatives as p13k inhibitors
BR112012020693A2 (pt) derivados de ciclobutano e metilciclobutano como inibidores de janus quinase
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
JO3419B1 (ar) مركبات بيريدوبيرازين مضادة للسرطان من خلال تثبيط إنزيمات كيناز fgfr
BR112012011528A2 (pt) métodos para inibir uma proteína quinase e para tratar uma doença associada com atividade de quinase, e, composto
BR112012010186B8 (pt) derivados de heteroarila contendo n como inibidores de quinase jak3 e composição farmacêutica compreendendo os mesmos
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
EA201390381A1 (ru) Триазиноксадиазолы
CO6771439A2 (es) Inhibidores de benzodioxano de la producción de leucotrieno
MX347241B (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO RJ860140134878 DE 11/08/2014 COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, UMA VEZ QUE JA FOI CONCEDIDO O EXAME PRIORITARIO DO PEDIDO DE PATENTE.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements